Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359033 | 0.67 | HPGD (0.40) | — | |
| SCHEMBL5359042 | 0.65 | HPGD (0.40) | — | |
| SCHEMBL3290356 | 0.63 | ALDH1A1 (0.35) | NUDT1MAPK8 | |
| SCHEMBL3396015 | 0.60 | KMT2A (0.43) | — | |
| SCHEMBL9396189 | 0.59 | NPSR1 (0.44) | — | |
| SCHEMBL8697727 | 0.59 | ALDH1A1 (0.53) | — | |
| SCHEMBL28569434 | 0.59 | HSP90AA1 (0.39) | — | |
| SCHEMBL18072297 | 0.59 | NUDT1 (1.00) | NUDT1MAPK8 | |
| SCHEMBL18049860 | 0.58 | NUDT1 (0.56) | NUDT1TLR8TLR7 | |
| SCHEMBL28022609 | 0.58 | L3MBTL1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285543-B2 | Purine inhibitors of fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20050277619-A1 | Novel purine inhibitors of fructose-1,6-bisphosphatase | DANG QUN | 2005-12-15 | — | — | US | disclosed |
| US-6967193-B1 | Purine inhibitors of fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-6284748-B1 | ANTIDIABETIC AGENT | METABASIS THERAPEUTICS, INC. | 2001-09-04 | — | — | US | disclosed |
| WO-1998039344-A9 | NOVEL PURINE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | — | 1999-01-21 | — | — | WO | disclosed |
| WO-1998039344-A1 | NOVEL PURINE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277619-A1 | Novel purine inhibitors of fructose-1,6-bisphosphatase | FBP1, PNP, PPA1 | NUDT1 47/4885MAPK8 1482/4885TLR8 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.